Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Up 88.1% in February

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 184,900 shares, a growth of 88.1% from the February 13th total of 98,300 shares. Based on an average daily volume of 79,200 shares, the short-interest ratio is currently 2.3 days. Currently, 10.8% of the company’s shares are short sold.

Creative Medical Technology Stock Down 14.8 %

NASDAQ:CELZ opened at $3.00 on Friday. Creative Medical Technology has a 52 week low of $1.96 and a 52 week high of $6.90. The stock’s fifty day moving average is $3.69 and its two-hundred day moving average is $3.28. The stock has a market capitalization of $6.97 million, a price-to-earnings ratio of -0.79 and a beta of 1.70.

Hedge Funds Weigh In On Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Geode Capital Management LLC acquired a new stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,308 shares of the company’s stock, valued at approximately $25,000. Geode Capital Management LLC owned 0.59% of Creative Medical Technology as of its most recent filing with the Securities and Exchange Commission (SEC). 1.42% of the stock is owned by institutional investors and hedge funds.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.